399 related articles for article (PubMed ID: 21193681)
1. Meta-analysis of Renin-Angiotensin-aldosterone blockade for heart failure in presence of preserved left ventricular function.
Meune C; Wahbi K; Duboc D; Weber S
J Cardiovasc Pharmacol Ther; 2011; 16(3-4):368-75. PubMed ID: 21193681
[TBL] [Abstract][Full Text] [Related]
2. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
3. Prognostic benefit of beta-blockers in patients not receiving ACE-Inhibitors.
Krum H; Haas SJ; Eichhorn E; Ghali J; Gilbert E; Lechat P; Packer M; Roecker E; Verkenne P; Wedel H; Wikstrand J
Eur Heart J; 2005 Oct; 26(20):2154-8. PubMed ID: 16014644
[TBL] [Abstract][Full Text] [Related]
4. Discharge use of angiotensin receptor blockers provides comparable effects with angiotensin-converting enzyme inhibitors on outcomes in patients hospitalized for heart failure.
Tsuchihashi-Makaya M; Furumoto T; Kinugawa S; Hamaguchi S; Goto K; Goto D; Yamada S; Yokoshiki H; Takeshita A; Tsutsui H;
Hypertens Res; 2010 Mar; 33(3):197-202. PubMed ID: 19960016
[TBL] [Abstract][Full Text] [Related]
5. Effect of statins, angiotensin-converting enzyme inhibitors, and beta blockers on survival in patients >or=65 years of age with heart failure and preserved left ventricular systolic function.
Shah R; Wang Y; Foody JM
Am J Cardiol; 2008 Jan; 101(2):217-22. PubMed ID: 18178410
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
7. Advances in the treatment of heart failure with a preserved ejection fraction.
Das A; Abraham S; Deswal A
Curr Opin Cardiol; 2008 May; 23(3):233-40. PubMed ID: 18382212
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
Grothusen A; Divchev D; Luchtefeld M; Schieffer B
Minerva Cardioangiol; 2009 Dec; 57(6):773-85. PubMed ID: 19942847
[TBL] [Abstract][Full Text] [Related]
9. Angiotensin receptor blockade with candesartan in heart failure: findings from the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme.
Ostergren JB
J Hypertens Suppl; 2006 Mar; 24(1):S3-7. PubMed ID: 16601570
[TBL] [Abstract][Full Text] [Related]
10. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure).
van Veldhuisen DJ; Cohen-Solal A; Böhm M; Anker SD; Babalis D; Roughton M; Coats AJ; Poole-Wilson PA; Flather MD;
J Am Coll Cardiol; 2009 Jun; 53(23):2150-8. PubMed ID: 19497441
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure and chronic kidney disease.
Berger AK; Duval S; Manske C; Vazquez G; Barber C; Miller L; Luepker RV
Am Heart J; 2007 Jun; 153(6):1064-73. PubMed ID: 17540211
[TBL] [Abstract][Full Text] [Related]
12. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials.
Young JB; Dunlap ME; Pfeffer MA; Probstfield JL; Cohen-Solal A; Dietz R; Granger CB; Hradec J; Kuch J; McKelvie RS; McMurray JJ; Michelson EL; Olofsson B; Ostergren J; Held P; Solomon SD; Yusuf S; Swedberg K;
Circulation; 2004 Oct; 110(17):2618-26. PubMed ID: 15492298
[TBL] [Abstract][Full Text] [Related]
13. Optimization of heart FailUre medical Treatment after hospital discharge according to left ventricUlaR Ejection fraction: the FUTURE survey.
Cohen Solal A; Leurs I; Assyag P; Beauvais F; Clerson P; Contre C; Thebaut JF; Genoun M;
Arch Cardiovasc Dis; 2012; 105(6-7):355-65. PubMed ID: 22800720
[TBL] [Abstract][Full Text] [Related]
14. Effects of renin-angiotensin system blockade on mortality and hospitalization in heart failure with preserved ejection fraction.
Agarwal V; Briasoulis A; Messerli FH
Heart Fail Rev; 2013 Jul; 18(4):429-37. PubMed ID: 22678768
[TBL] [Abstract][Full Text] [Related]
15. Effect of inhibition of the renin-angiotensin system on development of type 2 diabetes mellitus (meta-analysis of randomized trials).
Andraws R; Brown DL
Am J Cardiol; 2007 Apr; 99(7):1006-12. PubMed ID: 17398202
[TBL] [Abstract][Full Text] [Related]
16. Tissue angiotensin-converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: a pooled meta-analysis of randomized placebo-controlled clinical trials.
Saha SA; Molnar J; Arora RR
Diabetes Obes Metab; 2008 Jan; 10(1):41-52. PubMed ID: 18095949
[TBL] [Abstract][Full Text] [Related]
17. Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
McMurray JJ; Young JB; Dunlap ME; Granger CB; Hainer J; Michelson EL; Earle S; Olofsson B; Ostergren J; Yusuf S; Swedberg K; Pfeffer MA;
Am Heart J; 2006 May; 151(5):985-91. PubMed ID: 16644319
[TBL] [Abstract][Full Text] [Related]
18. A review of heart failure management in the elderly population.
Cheng JW; Nayar M
Am J Geriatr Pharmacother; 2009 Oct; 7(5):233-49. PubMed ID: 19948300
[TBL] [Abstract][Full Text] [Related]
19. ACE inhibitors in heart failure: what more do we need to know?
Demers C; Mody A; Teo KK; McKelvie RS
Am J Cardiovasc Drugs; 2005; 5(6):351-9. PubMed ID: 16259523
[TBL] [Abstract][Full Text] [Related]
20. Angiotensin inhibition in heart failure.
McMurray JJ
J Renin Angiotensin Aldosterone Syst; 2004 Sep; 5 Suppl 1():S17-22. PubMed ID: 15526237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
